Europe’s largest company, Novo Nordisk, saw its shares fall by 7% at market open following a disappointing second-quarter earnings report. The Danish pharmaceutical firm has trimmed its operating profit forecast for 2024, despite an upgrade in net sales. This suggests that rising supply may have increased price pressure, while substantial investment in new plants has impacted its profit margin. NumbersFor the second quarter, Novo Nordisk reported revenue of 68.06 billion Danish Kroner (€9.12bn), a 25% increase from last year at constant exchange rates (CER), but it fell short of the expected 2…